Key facts
- Glutensens’s last known valuation is $4.9M (Mar 2025).
- It has raised $1.1M; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include CDP Venture Capital (Rome), Farming Future, G-Factor, INNOVIT (San Francisco), Invitalia — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Glutensens
- ·The full record, as it builds
Funding rounds
No funding rounds for Glutensens are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Glutensens
Developer of a portable gluten-detection device designed for real-time food safety testing at the point of consumption. The company's platform employs biosensor technology capable of identifying trace gluten presence in both simple and complex cooked foods within minutes, requiring no specialist training to operate, and has been developed in collaboration with academic and research institutions to ensure validated, certifiable accuracy, enabling celiac and gluten-sensitive consumers, food service professionals, and producers to confidently verify meal safety without compromising health or convenience.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Milan, Italy
- Founded
- 2023
- Employees
- 4
- Website
- glutensens.it/
- Ownership
- Privately Held (backing)
Glutensens doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Glutensens shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Glutensens in its N-PORT filings yet. We sweep new filings monthly.